Trivalent chromium: assessing the genotoxic risk of an essential trace element and widely used human and animal nutritional supplement.

Trivalent chromium [Cr(III)] is recognized as an essential nutrient, and is widely used as a nutritional supplement for humans and animals. Recent reports of the induction of genetic damage in cultured cells exposed to Cr(III) compounds in vitro have heightened the concern that Cr(III) compounds may exert genotoxic effects under certain conditions, raising the question of the relative benefit versus risk of dietary and feed supplementation practices. We have reviewed the literature since 1990 on genotoxic effects of Cr(III) compounds to determine whether recent findings provide a sufficient weight of evidence to modify the conclusions about the safety of this dietary supplement reached in the several comprehensive reviews conducted during the period 1990-2004. The extensive literature on genotoxic effects of Cr(III) compounds includes many instances of conflicting information, with both negative and positive findings often reported in similar test systems. Outcomes of in vitro tests conducted with Cr(III) in cultured cells are quite variable regardless of the chemical form of the chromium compound tested. The in vitro data show that Cr(III) has the potential to react with DNA and to cause DNA damage in cell culture systems, but under normal circumstances, restricted access of Cr(III) to cells in vivo limits or prevents genotoxicity in biological systems. The available in vivo evidence suggests that genotoxic effects are very unlikely to occur in humans or animals exposed to nutritional or to moderate recommended supplemental levels of Cr(III). However, excessive intake of Cr(III) supplements does not appear to be warranted at this time. Thus, like other nutrients that have exhibited genotoxic effects in vitro under high exposure conditions, nutritional benefits appear to outweigh the theoretical risk of genotoxic effects in vivo at normal or modestly elevated physiological intake levels.

Chronic inhalation exposure of rats for up to 104 weeks to a non-carbon-based magnetite photocopying toner.

Male and female Han Wistar rats were exposed for 6 h/day, 5 days/week for 13 or 104 weeks (whole body) to a magnetite photocopying toner. The toner contained 45% to 50% magnetite, with 45% to 50% styrene acrylic resin and less than 5% external additives, including hydrophobic amorphous silica and proprietary surface functional modifiers. Exposure levels were 1, 5, and 25 mg/m(3) for the 13-week study and 1, 4, and 16 mg/m(3) for the 104-week study. Lung toner burdens averaged 36, 288, and 604 microg per lung after 104 weeks' exposure at 1, 4, and 16 mg/m(3). The lung burdens were lower than have been reported in a similar study with a carbon-based toner. There were no significant effects on weight gain or food consumption in either study, or on clinical pathology parameters examined in the 13-week study. After 104 weeks' exposure at 16 mg/m(3), macroscopic examination revealed dark discoloration of the lungs and associated lymph nodes. Lung weights were significantly elevated by 21% and 14% for male and female rats, respectively. Microscopic findings indicative of a mild inflammatory response were similar in both studies, and included the presence of black-pigmented macrophages in the lungs and tracheobronchial and mediastinal lymph nodes; increased incidences of perivascular/peribronchiolar inflammatory cell infiltration; inflammation of the alveolar ducts (characterized by aggregations of black-pigmented alveolar macrophages and interstitial lymphocytic infiltration); increased cellularity of the bronchiole-associated lymphoid tissue; and a few instances of alveolar ciliated metaplasia. The 104-week study showed no increase in the incidence of pulmonary tumors.

Chromium picolinate does not produce chromosome damage in CHO cells.

Chromium picolinate (CrPic, Chromax) is a dietary supplement that has been commercially available for the past two decades. CrPic has potential benefits for reducing insulin dependence in diabetics by increasing sensitivity of insulin receptors and in stimulating insulin binding. In this study, CrPic was tested for its ability to produce chromosomal aberrations in vitro using Chinese hamster ovary K1 (CHO) cells. CHO cells were exposed to a range of cytotoxic to non-cytotoxic concentrations of CrPic for 4 or 20h in the absence of metabolic (S9) activation or for 4h in the presence of S9 activation. CrPic was solubilized with dimethyl sulfoxide (DMSO) to attain the highest possible solubility for maximizing the test doses. Cells were treated with 96.25, 192.5, 385 or 770 microg/mL of CrPic for 4 h in the presence of S9 activation, and for 4 or 20 h in the absence of S9 activation. A distinct precipitate of CrPic was evident in the cell culture medium at 770 microg/mL, which was the highest dose tested. Results showed no statistically significant increases in structural or numerical chromosome aberrations were produced at any test dose level with CrPic in 4-h treatments up to a precipitating dose of 770 microg/mL in either the presence or absence of S9 activation. Additionally no aberrations were observed up to 385 microg/mL (the maximum analyzable dose) following treatment for 20 h in the absence of S9 activation. The percentage of cells with structural or numerical aberrations in CrPic treated cultures was not statistically different (p>0.05) from that quantified in controls at any dose level. The absence of significant differences from control levels demonstrates that CrPic did not induce structural or numerical chromosome aberrations up to doses that were insoluble in the culture medium.

Lack of mutagenicity of chromium picolinate in the hypoxanthine phosphoribosyltransferase gene mutation assay in Chinese hamster ovary cells.

Chromium picolinate (CrPic, Chromax) is a dietary supplement that is stable and more bioavailable than other commercially available forms of chromium. Chromium supplementation is known to enhance the action of insulin, particularly in insulin resistance and type 2 diabetes mellitus. A previous study reported that CrPic produced increases in mutations of the hypoxanthine phosphoribosyltransferase (Hprt) gene in Chinese hamster ovary (CHO) cell mutation tests. This study, however, evaluated CrPic produced by the testing laboratory and used an atypical 48 h exposure period for this test system. The current study evaluated the mutagenic potential of the most widely utilized commercial form of CrPic in CHO/Hprt mutation tests following International Conference on Harmonisation (ICH) Guidelines (+/-S9 metabolic activation with a 5h exposure) in addition to repeating the test with a 48 h exposure period -S9 activation. CrPic was suspended in dimethyl sulfoxide (DMSO) up to a concentration of 50 mg/mL; exposures were conducted under conditions in which precipitate was not evident and under conditions in which some precipitate of CrPic was visually evident in the cell culture medium at the highest concentrations (500 microg/mL). The concentrations evaluated for mutagenicity ranged from 15.6 to 500 microg/mL (+S9 and -S9) for the 5 h exposure and 31.3-500 microg/mL for the 48 h exposure (-S9). Only a slight degree of cytotoxicity was seen in the standard tests up to the limit of solubility in the medium. Toxicity, i.e., cloning efficiency < or =50% of the solvent control, but no mutagenic increases were observed at 500 microg/mL following a 48 h exposure period. The results of these studies showed that CrPic was non-mutagenic in two independent CHO/Hprt assays and in an assay using a 48 h exposure period.